Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 10, Octobre 2011
Page(s) 850 - 858
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20112710013
Publié en ligne 21 octobre 2011
  1. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy : oncogene and non-oncogene addiction. Cell 2009 ; 136 : 823–837. [CrossRef] [PubMed] [Google Scholar]
  2. Waldmann TA. Immunotherapy : past, present and future. Nat Med 2003 ; 9 : 269–277. [CrossRef] [PubMed] [Google Scholar]
  3. Van Leeuwen MT, Webster AC, McCredie MRE, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. Br Med J 2010 ; 340 : c570. [CrossRef] [PubMed] [Google Scholar]
  4. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009 ; 27 : 3489–3495. [CrossRef] [PubMed] [Google Scholar]
  5. Krauze MT, Tarhini A, Gogas H, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol 2011 ; 33 : 385–391. [CrossRef] [PubMed] [Google Scholar]
  6. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008 ; 8 : 299–308. [CrossRef] [PubMed] [Google Scholar]
  7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 ; 10 : 909–915. [CrossRef] [PubMed] [Google Scholar]
  8. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996 ; 271 : 1734–1736. [CrossRef] [PubMed] [Google Scholar]
  9. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 2005 ; 23 : 8968–8977. [CrossRef] [PubMed] [Google Scholar]
  10. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010 ; 16 : 1042–1048. [CrossRef] [PubMed] [Google Scholar]
  11. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 2010 ; 37 : 450–454. [CrossRef] [PubMed] [Google Scholar]
  12. Ribas A, Hauschild A, Kefford R. Phase III, open-label, randomized, comparative study of tremelimumab(CP-675, 206) and chemotherapy (temozolomide or dacarbazine) in patients with advanced melanoma. J Clin Oncol 2008 ; 26 : 15S (LBA9011 abstract). [Google Scholar]
  13. Marshall MA, Ribas A, Huang B. Evaluation of baselineserum C-reactive protein and benefit from tremelimumabcompared to chemotherapy in first-line melanoma. J Clin Oncol 2010 ; 28 : 15S (2609 abstract). [CrossRef] [Google Scholar]
  14. Ménard C, Ghiringhelli F, Roux S, et al. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma : surrogate marker of efficacy of tremelimumab? Clin Cancer Res 2008 ; 14 : 5242–5249. [CrossRef] [PubMed] [Google Scholar]
  15. Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009 ; 15 : 6267–6276. [CrossRef] [PubMed] [Google Scholar]
  16. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005 ; 23 : 6043–6053. [CrossRef] [PubMed] [Google Scholar]
  17. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007 ; 13 : 6681–6688. [CrossRef] [PubMed] [Google Scholar]
  18. Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2011 ; 28 : 489–498. [CrossRef] [PubMed] [Google Scholar]
  19. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008 ; 105 : 3005–3010. [CrossRef] [PubMed] [Google Scholar]
  20. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005 ; 12 : 1005–1016. [CrossRef] [PubMed] [Google Scholar]
  21. O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma : a multicenter single-arm phase II study. Ann Oncol 2010 ; 21 : 1712–1717. [CrossRef] [PubMed] [Google Scholar]
  22. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003 ; 100 : 8372–8377. [CrossRef] [Google Scholar]
  23. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine : immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011 ; 17 : 896–906. [CrossRef] [PubMed] [Google Scholar]
  24. Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008 ; 26 : 5950–5956. [CrossRef] [PubMed] [Google Scholar]
  25. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009 ; 15 : 5591–5598. [CrossRef] [PubMed] [Google Scholar]
  26. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010 ; 11 : 155–164. [CrossRef] [PubMed] [Google Scholar]
  27. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711–723. [CrossRef] [PubMed] [Google Scholar]
  28. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364 : 2517–2526. [CrossRef] [PubMed] [Google Scholar]
  29. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008 ; 5 : 557–561. [CrossRef] [PubMed] [Google Scholar]
  30. Schartz NEC, Farges C, Madelaine I, et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010 ; 20 : 247–250. [PubMed] [Google Scholar]
  31. Di Giacomo AM, Danielli R, Calabrò L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011 ; 60 : 467–477. [CrossRef] [PubMed] [Google Scholar]
  32. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995 ; 270 : 985–988. [CrossRef] [PubMed] [Google Scholar]
  33. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005 ; 23 : 741–750. [CrossRef] [PubMed] [Google Scholar]
  34. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006 ; 24 : 2283–2289. [CrossRef] [PubMed] [Google Scholar]
  35. Smith FO, Goff SL, Klapper JA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother 2007 ; 30 : 130. [CrossRef] [PubMed] [Google Scholar]
  36. Berman D, Parker SM, Siegel J, et al., Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010 ; 10 : 11. [PubMed] [Google Scholar]
  37. Harmankaya K, Erasim C, Koelblinger C, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 2010 ; 1er juillet (online). [Google Scholar]
  38. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009 ; 15 : 7412–7420. [CrossRef] [PubMed] [Google Scholar]
  39. Small EJ, Tchekmedyian NS, RiniBI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007 ; 13 : 1810–1815. [CrossRef] [PubMed] [Google Scholar]
  40. Hamid O, Chasalow SD, Tsuchihashi Z, et al. Association of baseline and on-study tumor biopsy markers with clinical activity in patients wih advanced melanoma treated with ipilimumab. J Clin Oncol 2009 ; 27 : 15S (9008 abstract). [CrossRef] [Google Scholar]
  41. Liakou CI, Kamat A, Tang DN, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008 ; 105 : 14987–14992. [CrossRef] [Google Scholar]
  42. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting : lymphocyte count after 2 doses correlates with survival. Cancer 2010 ; 116 : 1767–1775. [CrossRef] [PubMed] [Google Scholar]
  43. Breunis WB, Tarazona-Santos E, Chen R, et al. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 2008 ; 31 : 586–590. [CrossRef] [PubMed] [Google Scholar]
  44. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009 ; 27 : 1075–1081. [CrossRef] [PubMed] [Google Scholar]
  45. Dumaz N, Bagot M, Bensussan A. Quand CRAF remplace BRAF dans le mélanome. Med Sci (Paris) 2011 ; 27 : 817–819. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  46. Olive D, Le Thi S, Xerri L, et al. Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire. Med Sci (Paris) 2011 ; 27 : 842–849. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  47. Rousseaux S, Reynoird N, Gaucher J, Khochbin S. L’intrusion des régulateurs de l’épigénome mâle dans les cellules somatiques cancéreuses. Med Sci (Paris) 2008 ; 24 : 735–741. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  48. Tartour E, Sandoval F, Bonnefoy JY, Fridman WH. Immunothérapie des cancers : succès récents et perspectives. Med Sci (Paris) 2011 ; 27 : 833–841. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  49. Anticorps monoclonaux en thérapeutique. Med Sci (Paris) 2009 ; 25 : 995–1196. [CrossRef] [EDP Sciences] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.